Database : MEDLINE
Search on : lymphoproliferative and disorders [Words]
References found : 12022 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1203 go to page                         

  1 / 12022 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524307
[Au] Autor:Cowan AJ; Johnson CK; Libby EN
[Ad] Address:Division of Medical Oncology, University of Washington, Seattle, WA, USA.
[Ti] Title:Plasma Cell Diseases and Organ Transplant: A Comprehensive Review.
[So] Source:Am J Transplant;, 2018 Mar 09.
[Is] ISSN:1600-6143
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Plasma cell diseases are a class of hematologic diseases that are sometimes present as pre-existing diagnoses prior to organ transplantation, causative factors leading to a need for organ transplantation, or may occur post-transplant as part of the spectrum of post-transplant lymphoproliferative disorders. Herein, we review the most common plasma cell diseases, both as co-existing with other causes of organ failure, but also as a primary underlying cause for organ failure. In many cases, treatment of the underlying clonal disease may be indicated before proceeding with organ transplant. This review aims to provide current and relevant data regarding the management of these conditions in the organ transplant patient, for transplant providers and those who take care of these patients. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/ajt.14731

  2 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518251
[Au] Autor:Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs; Dietrich PY
[Ad] Address:Centre of Oncology, University Hospitals of Geneva, Switzerland.
[Ti] Title:Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
[So] Source:Swiss Med Wkly;148:w14596, 2018 Mar 08.
[Is] ISSN:1424-3997
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a potentially life-threatening complication of transplantation occurring in the setting of immunosuppression and oncogenic viral infections. However, little is known about the cumulative incidence, histological subtypes, risk determinants and outcome of PTLD in solid organ transplant (SOT) recipients in Switzerland. METHODS: This retrospective observational study investigated adult SOT recipients from two sequential cohorts, the pre-SCTS (Swiss Transplant Cohort Study) series, with data collected from January 1986 to April 2008, and the STCS series, with data collected from May 2008 to December 2014 in Switzerland. SOT recipients were cross-referenced with the data of all the patients with a lymphoma diagnosis in each transplant centre and with the data of the Swiss Transplant Cohort Study (STCS) to determine the cumulative incidence of PTLD, pre-therapeutic clinical features, clinical course and outcome. Kaplan-Meier analysis was performed for overall survival after PTLD. RESULTS: We identified 79 cases of PTLD during the study period in the two cohorts: pre-STCS from 1986 to 2008 (n = 62) and STCS from 2008 to 2014 (n = 17). Histological subgroups included: early lesions (pre-STCS n = 2, STCS n = 0); polymorphic PTLD (pre-STCS n = 8, STCS n = 7); monomorphic PTLD (pre-STCS n = 47, STCS n = 10), and Hodgkin's lymphoma (pre-STCS n = 5, STCS n = 0). Median time to PTLD diagnosis was 90 months (range 3-281 months) and 14 months (range 2-59 months) in the pre-STCS and STCS cohorts, respectively. Median follow-up after transplantation was 141 months for the pre-STCS patients and 33 months for the STCS patients. Cumulative incidences of PTLD during the STCS period at 0.5, 1 and 5 years were 0.17% (95% confidence interval 0.07-0.46%), 0.22% (0.09-0.53%) and 0.96% (0.52-1.80%), respectively. For the pre-STCS case series, it was not possible to estimate the incidence rate of PTLD. Survival after PTLD diagnosis was 80% (68-87%) at 1 year and 56% (42-68%) at 5 years for the pre-STCS and STCS cohorts combined. CONCLUSIONS: At 5 years, the cumulative incidence of PTLD, regardless of the organ transplanted, was only 0.96% in the STCS cohort, which is lower than that reported in the literature.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review

  3 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28466385
[Au] Autor:Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
[Ad] Address:BMT Unit, Department of Hematology, Cebeci Hospital, School of Medicine, Ankara University, Dikimevi, 06590, Ankara, Turkey. erdenatilla@gmail.com.
[Ti] Title:Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
[So] Source:Int J Hematol;106(3):426-430, 2017 Sep.
[Is] ISSN:1865-3774
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. The overall response rate was 25%, while the disease progressed and relapsed after transplant in 38% of patients. Allo-HSCT may be a reasonable treatment option in the relapsed/refractory stage.
[Mh] MeSH terms primary: Allografts
Hematopoietic Stem Cell Transplantation
Mycosis Fungoides/therapy
Sezary Syndrome/therapy
Skin Neoplasms/therapy
[Mh] MeSH terms secundary: Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Retrospective Studies
Skin Neoplasms/rehabilitation
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE
[do] DOI:10.1007/s12185-017-2245-x

  4 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516290
[Au] Autor:Okada K; Asakura S; Yano T; Kishimoto T
[Ad] Address:Internal Medicine Department, Okayama Rousai Hospital, 1-10-25 Chikko, Midori-machi, Minamiku, Okayama city, Okayama, 702-8055, Japan. kimi_caterpillar0120@yahoo.co.jp.
[Ti] Title:EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus.
[So] Source:Int J Hematol;, 2018 Mar 07.
[Is] ISSN:1865-3774
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:Primary effusion lymphoma (PEL) is a rare type of extranodal lymphoma, typically of a B-cell origin, which presents as lymphomatous effusion with no nodal enlargement or tumor masses. The development PEL is universally associated with human herpes virus-8 (HHV-8) infection. Cases of HHV-8-negative primary lymphomatous effusion have recently been reported and referred to as HHV-8-unrelated PEL-like lymphoma. Some cases of this disease have been reported in iatrogenic immunocompromised patients. The mechanisms responsible for the inhibitory effects of the discontinuation of immunosuppressants other than methotrexate (MTX) against the disease, which have been demonstrated for MTX-associated lymphoproliferative disorders, have not yet been elucidated. We describe a case of PEL-like lymphoma that developed in the course of antisynthetase syndrome and was treated with tacrolimus. A single dose of systemic chemotherapy did not improve lymphomatous effusion, whereas the discontinuation of tacrolimus resulted in the long-term remission of this disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1007/s12185-018-2426-2

  5 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29385417
[Au] Autor:Fang H; Chiu A; Reichard KK
[Ad] Address:Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN.
[Ti] Title:Crystal-Storing Histiocytosis in Bone Marrow: A Clinicopathologic Study of Eight Cases and Review of the Literature.
[So] Source:Am J Clin Pathol;149(2):148-163, 2018 Jan 29.
[Is] ISSN:1943-7722
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives: We report the clinicopathologic characteristics of eight cases of crystal-storing histiocytosis (CSH) with bone marrow (BM) involvement (BM-CSH) and review CSH cases published in the English literature. Methods: We queried our pathology database for BM cases with CSH mentioned in the final diagnosis/comments from June 2011 to August 2016. Results: Eight cases of BM-CSH were identified. The underlying diagnoses consisted predominantly of plasma cell disorders (88%) associated with monotypic κ light chain. In BM aspirates, crystals within histiocytes exhibited a morphologic spectrum including brightly eosinophilic, needle-like, or globule-like. In BM core biopsies, the histiocytes were often in aggregates with intracellular needle-like and/or globular, refractile inclusions. Conclusions: BM-CSH is a rare phenomenon and exhibits a heterogeneous crystalline and histiocytic appearance warranting accurate recognition to avoid misinterpretation of a granulomatous condition or storage disorder. In addition, prompt assessment for an underlying B-cell lymphoma or clonal plasmacytic neoplasm is indicated.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/ajcp/aqx150

  6 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29228090
[Au] Autor:Cassidy DP; Vega F; Chapman JR
[Ad] Address:Division of Hematopathology, Department of Pathology and Laboratory Medicine.
[Ti] Title:Epstein-Barr Virus-Positive Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue in the Posttransplant Setting: An Immunodeficiency-Related (Posttransplant) Lymphoproliferative Disorder?
[So] Source:Am J Clin Pathol;149(1):42-49, 2017 Dec 20.
[Is] ISSN:1943-7722
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives: Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of hematolymphoid proliferations arising in the context of chronic immunosuppression. The common and indolent B-cell lymphomas, including extranodal marginal zone lymphomas (ENMZLs) of mucosa-associated lymphoid tissue (MALT), are excluded from the category of PTLD in the current World Health Organization classification. Methods: We report a case of Epstein-Barr virus (EBV)-positive bronchial-associated lymphoid tissue (BALT) lymphoma involving the lungs of a transplant patient. Results: Aside from history of cardiac transplant, young patient age, and EBV positivity, the histopathologic findings were indistinguishable from usual BALT lymphoma. Conclusions: We review the literature of ENMZL occurring in immunocompromised patients and present this case for consideration that this specific entity is a PTLD. We believe that additional studies might lend strength to the hypothesis that this particular group of EBV-positive, posttransplant ENMZLs merits classification and management as PTLDs.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/ajcp/aqx134

  7 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29157618
[Au] Autor:Wu D; Lim MS; Jaffe ES
[Ad] Address:Department of Laboratory Medicine, University of Washington, 825 Eastlake Avenue East, Room G-7800, Seattle, WA 98109, USA. Electronic address: dwu2@uw.edu.
[Ti] Title:Pathology of Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):37-52, 2018 02.
[Is] ISSN:1558-1977
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The term Castleman disease encompasses several distinct lymphoproliferative disorders with different underlying disease pathogenesis, and clinical outcomes. It includes unicentric and multicentric diseases with limited versus significant systemic symptoms, respectively. Importantly, the histopathologic features encountered in the various forms of Castleman disease are diverse, and for the most part, lack specificity, because they are seen to varying degrees in different clinical variants of Castleman disease, and in reactive (autoimmune/infectious) and malignant (lymphoma) contexts. Accordingly, accurate clinical diagnosis of Castleman disease requires careful and thorough clinicopathologic correlation. An overview of the key histopathologic features of Castleman disease is presented.
[Mh] MeSH terms primary: Castleman Disease/classification
Castleman Disease/diagnosis
Castleman Disease/pathology
[Mh] MeSH terms secundary: Humans
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:171122
[St] Status:MEDLINE

  8 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29157613
[Au] Autor:Fajgenbaum DC; Shilling D
[Ad] Address:Division of Translational Medicine and Human Genetics, Hospital of the University of Pennsylvania, 3400 Spruce Street, Silverstein 5, Suite S05094, Philadelphia, PA 19104, USA. Electronic address: davidfa@pennmedicine.upenn.edu.
[Ti] Title:Castleman Disease Pathogenesis.
[So] Source:Hematol Oncol Clin North Am;32(1):11-21, 2018 02.
[Is] ISSN:1558-1977
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Castleman disease (CD) describes a group of heterogeneous disorders with common lymph node histopathologic features, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. The cause and pathogenesis of the four subtypes of CD (unicentric CD; human herpesvirus-8-associated multicentric CD; polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes [POEMS]-associated multicentric CD; and idiopathic multicentric CD) vary considerably. This article provides a summary of our current understanding of the cause, cell types, signaling pathways, and effector cytokines implicated in the pathogenesis of each subtype.
[Mh] MeSH terms primary: Castleman Disease
Cytokines/blood
Herpesviridae Infections
Herpesvirus 8, Human/metabolism
Lymph Nodes
Neoplasm Proteins/blood
Signal Transduction
[Mh] MeSH terms secundary: Castleman Disease/blood
Castleman Disease/physiopathology
Castleman Disease/virology
Herpesviridae Infections/blood
Herpesviridae Infections/physiopathology
Humans
Lymph Nodes/metabolism
Lymph Nodes/physiopathology
Lymph Nodes/virology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Cytokines); 0 (Neoplasm Proteins)
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:171122
[St] Status:MEDLINE

  9 / 12022 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29511289
[Au] Autor:Gallardo F; Bertran J; López-Arribillaga E; González J; Menéndez S; Sánchez I; Colomo L; Iglesias M; Garrido M; Santamaría-Babí LF; Torres F; Pujol RM; Bigas A; Espinosa L
[Ad] Address:Dermatology Department, Parc de Salut Mar-Hospital del Mar, Barcelona, Spain.
[Ti] Title:Novel phosphorylated TAK1 species with functional impact on NF-κB and ß-catenin signaling in human Cutaneous T-cell lymphoma.
[So] Source:Leukemia;, 2018 Feb 22.
[Is] ISSN:1476-5551
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and ß-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Blocking PP1 activity, both pharmacologically and genetically, resulted in TAK1 hyperphosphorylation at residues T344, S389, T444, and T511, which have functional impact on canonical NF-κB signaling. Inhibition of TAK1 precluded NF-κB and ß-catenin signaling and induced apoptosis of CTCL cell lines and primary Sézary syndrome cells both in vitro and in vivo. Detection of phosphorylated TAK1 at T444 and T344 is associated with the presence of lymphoma in a set of 60 primary human samples correlating with NF-κB and ß-catenin activation. These results identified TAK1 as a potential biomarker and therapeutic target for CTCL therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1038/s41375-018-0066-4

  10 / 12022 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29510190
[Au] Autor:Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
[Ad] Address:Department of Dermatology and Venerology, Peking University First Hospital, Beijing 100034, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, China.
[Ti] Title:SATB1 defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with a T-helper-17 cytokine profile.
[So] Source:J Invest Dermatol;, 2018 Mar 03.
[Is] ISSN:1523-1747
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cutaneous CD30+ lymphoproliferative disorder (CD30+LPDs), including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (PCALCL), comprises the second most common group of cutaneous T cell lymphoma. Previously, we reported that special AT-rich sequence-binding protein1 (SATB1), a thymocyte specific chromatin organizer, was over-expressed and promoted malignant T-cell proliferation in a portion of CD30+LPDs. Here, we investigated the expression pattern of SATB1 in CD30+LPDs with a large cohort of patient samples, and examined the potential of SATB1 as a molecular marker to classify CD30+LPDs with differential clinicopathological behaviors. SATB1 expression was identified in the CD30+ anaplastic T cells in 11 of 12 (91.7%) LyP and 16 of 42 (38.1%) PCALCL cases. SATB1+ cases showed T-helper (Th)-17 polarization, together with more prominent epidermal hyperplasia and granulocytic infiltration. SATB1+ lesions responded better to combined treatment of methotrexate and interferon. SATB1 activated the expression of Th17 cytokines while repressing Th1 related genes. The heterogeneity in SATB1 expression across CD30+LPDs was associated with the extent of promoter DNA methylation. Hence, SATB1 expression defines a subtype of CD30+LPDs with characteristic pathobiology and prognosis. These data provide valuable insights into the heterogeneity of cutaneous T cell malignancies, which may lead to individualized therapy in the future.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher


page 1 of 1203 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information